Trifluoroacetic Acid
Trifluoroacetic acid is a corrosive organofluorine compound that is structurally analogous to, but stronger than, acetic acid. Available in various quantities and reagent grades, it is used in NMR spectroscopy, mass spectrometry, organic synthesis, etc.
Almost 100,000-fold more acidic than acetic acid, TFA is widely used in organic chemistry. TFA is used as a reagent in organic synthesis because of its properties: volatility, organic solvent solubility, and acidic strength. It is less oxidizing than sulfuric acid and is more readily available in its anhydrous form than some other acids . Other features include:
- Used in acid-catalyzed reactions, especially peptide synthesis (to cleave esters)
- Dissolves protein when mixed with liquid SO2
- Removes t-butyl derived side-chain protecting groups in Fmoc peptide synthesis
- Can remove the t-butoxycarbonyl protecting group in organic synthesis
- At low concentrations, acts as an ion-pairing agent for peptides and small proteins in organic compound liquid chromatography
- For acid-stable materials, can be a solvent for NMR spectroscopy
- Acts as a calibrant in mass spectrometry
- Used to produce trifluoroacetate salts
- An ingredient in adhesives, sealants, paints, and coatings
When TFA combines with bases and metals, especially light metals, a strong exothermic reaction occurs. When mixed with lithium aluminum hydride (LAH), the reaction is explosive.
Although nonflammable, TFA is corrosive to skin, eyes, and mucous membranes and requires careful use and handling. It is harmful when inhaled, causes severe skin burns and eye damage, and is toxic to aquatic organisms at even low concentrations.
TFA is also a product of the metabolic breakdown of the anesthetic agent halothane. It is the suspected cause of halothane-induced hepatitis.
Medchemexpress LLC Hth-01-091 Tfa | 2000209-42-5 | 98.64% | 499.43 | 1 MG
HTH-01-091 is a potent and selective maternal embryonic leucine zipper kinase (MELK) inhibitor, with an IC50 of 10.5 nM. It also inhibits PIM1/2/3, RIPK2, DYRK3, smMLCK, and CLK2. This compound can be used for breast cancer research.
- Potent and selective MELK inhibitor.
- Inhibits multiple kinases including PIM1/2/3, RIPK2, DYRK3, smMLCK, and CLK2.
- Suitable for breast cancer research.
Medchemexpress LLC WDR5-IN-4 TFA | 2749300-35-2 | 98.0% | 612.40 | 1 ML
WDR5-IN-4 TFA (Compound C6) is an inhibitor of the WIN site of chromatin-associated WD repeat-containing protein 5 (WDR5), with a Kd of 0.1 nM. It displaces WDR5 from chromatin and decreases the expression of associated genes, leading to translational inhibition and nucleolar stress. This compound also exhibits anti-cancer activity.
- Inhibits the proliferation of MLL1-rearranged cancer cells MV4:11 and K562 cells with GI50s of 3.20 μM and 25.4 μM respectively, when treated with 0-50 μM for 3 days.
- Arrests the cell cycle of MV4:11 at the sub-G1 phase and induces apoptosis in MV4:11 when treated with 2 μM for 6 days.
- Promotes Hox genes in hindbrains of Rnf220+/- mice at late embryonic stages with an intrauterine injection of 100 μg (single dose).
Medchemexpress LLC VTP-27999 (TFA) | 1013937-63-7 | 97.0% | C28H42ClF3N4O7 | 5 MG
VTP-27999 (TFA) is an alkyl amine Renin inhibitor useful for hypertension and end-organ diseases. This product is for research use only.
- Alkyl amine Renin inhibitor
- Useful for hypertension research
- Useful for end-organ diseases research
- For research use only
Medchemexpress LLC Ms15 TFA | C66H80F3N11O7S | 5 MG
MS15 TFA is a potent and selective AKT PROTAC degrader for research use only. It effectively inhibits AKT1, AKT2, and AKT3 activities, demonstrating bioavailability in mice through intraperitoneal administration.
- Potent and selective AKT PROTAC degrader
- Inhibits AKT1, -2, and -3 activities
- IC50 values: 798 nM (AKT-1), 90 nM (AKT-2), 544 nM (AKT-3)
- Bioavailable in mice via intraperitoneal administration
- Purity of 99.82%
Medchemexpress LLC Gln-AMS TFA | 99.9% | 588.47 | 100 MG
Gln-AMS (TFA) is a type Ia aminoacyl-tRNA synthetase (AARS) inhibitor, specifically inhibiting glutaminyl-tRNA synthetase (GlnRS) with a Ki of 1.32 μM.
- Inhibits glutaminyl-tRNA synthetase (GlnRS)
- Type Ia aminoacyl-tRNA synthetase (AARS) inhibitor
- White to off-white solid
- Purity of 99.85%
- Soluble in DMSO at 100 mg/mL
- Store at -20°C under nitrogen
Medchemexpress LLC Claramine (TFA) | 3030428-57-7 | 95.0% | 703.02 | 25 MG
Claramine TFA is a steroidal polyamine. It can regulate the properties of lipid membranes and protect cells from various biological toxins, including misfolded protein oligomers and toxins derived from biological proteins.
- Steroidal polyamine
- Regulates the properties of lipid membranes
- Protects cells from various biological toxins
Medchemexpress LLC VTP-27999 TFA | 1013937-63-7 | 97.00% | C28H42ClF3N4O7 | 25 MG
VTP-27999 TFA is a potent alkyl amine Renin inhibitor, recognized for its role in addressing hypertension and related end-organ diseases. This compound is primarily utilized in research settings to explore the mechanisms of renin-angiotensin-aldosterone system (RAAS) regulation. Its specific inhibitory action offers a valuable tool for studying cardiovascular conditions and developing novel therapeutic strategies.
- Potent alkyl amine renin inhibitor
- Useful for hypertension research
- Applicable in studies of end-organ diseases
- Supports research on RAAS regulation
- Aids in the development of cardiovascular therapies
Medchemexpress LLC NCGC00138783 TFA | 99.4% | C28H27F4N7O3S | 25 MG
NCGC00138783 TFA is a selective inhibitor targeting the CD47/SIRPα axis, directly blocking the interaction between the CD47 and SIRPα axis with an IC50 of 50 μM.
- Appearance: Solid
- Color: White to light yellow
- Molecular weight: 617.62
Apexbio Technology LLC cyclo(RLsKDK) TFA(Synonyms: cyclo(RLsKDK), Cyclic peptide RLsKDK, ADAM8 inhibitor peptide, Cyclo-Arg-Leu-Ser-Lys-Asp-Lys), 5mg.
Cyclo(RLsKDK) TFA is a cyclic pentapeptide inhibitor targeting the metalloproteinase ADAM8 a transmembrane protein frequently dysregulated in pathological conditions such as inflammation cancer and neurodegenerative diseases By specifically inhibiting ADAM8 enzymatic activity cyclo(RLsKDK) TFA may modulate disease-associated cellular processes This molecule holds promise as a research tool for studying ADAM8 function and as a potential therapeutic candidate in inflammatory disorders and oncology
Apexbio Technology LLC FSLLRY-NH2 TFA 245329-02-6 (free base) 25mg
FSLLRY-NH2 TFA is a synthetic peptide antagonist targeting protease-activated receptor 2 (PAR-2) It is designed to block PAR-2 activation thereby inhibiting intracellular signaling cascades such as calcium mobilization and MAP kinase activation that underlie inflammatory responses nociceptive transmission and immune modulation FSLLRY-NH2 TFA exerts its biological activity primarily through competitive binding to PAR-2 preventing receptor activation and downstream signaling events Based on these pharmacological properties FSLLRY-NH2 TFA holds research potential in the study of inflammation-associated disorders and pain pathways
Apexbio Technology LLC FSLLRY-NH2 TFA 245329-02-6 (free base) 5mg
FSLLRY-NH2 TFA is a synthetic peptide antagonist targeting protease-activated receptor 2 (PAR-2) It is designed to block PAR-2 activation thereby inhibiting intracellular signaling cascades such as calcium mobilization and MAP kinase activation that underlie inflammatory responses nociceptive transmission and immune modulation FSLLRY-NH2 TFA exerts its biological activity primarily through competitive binding to PAR-2 preventing receptor activation and downstream signaling events Based on these pharmacological properties FSLLRY-NH2 TFA holds research potential in the study of inflammation-associated disorders and pain pathways
Medchemexpress LLC OS-2966 10mg | 10mg
OS-2966 is a humanized antibody expressed in CHO cells targeting Integrin b1/ITGB1/CD29 OS-2966 carries a huIgG1 type heavy chain and a hu type light chain with a predicted molecular weight (MW) of 145 5 kDa The isotype control for OS-2966 can be referenced as Human IgG1 kappa Isotype Control (HY-P99001)
Medchemexpress LLC BIM 23042 (trifluoroacetate) | 00-00-0 | MFCD32666112 | 96.2% | 1192.45 g/mol | C63H73N11O9S2·xC2HF3O2 | 1 MG
BIM 23042 (trifluoroacetate) is a somatostatin-like octapeptide analogue that acts as a selective neuromedin B receptor (NMB-R/BB1) antagonist. It is supplied as the trifluoroacetate salt in solid form for research use in receptor pharmacology and intracellular calcium signaling studies.
- Selective neuromedin B receptor (NMB-R/BB1) antagonist.
- Somatostatin-like octapeptide structure as the trifluoroacetate salt.
- Purity approximately 96.2% by supplier analysis.
- White to off-white solid powder suitable for laboratory use.
- Store sealed away from moisture and light; powder stable at -80°C (2 years) or -20°C (1 year).